Lazard Capital Downgrades ABIOMED (ABMD) to Neutral
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
- Nasdaq leads Wall Street gains as SpaceX, Super Micro boost AI sentiment
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
- SpaceX, Tesla shares rise after Musk says committees exploring possible merger
- Brent falls as Iran's president discusses mediation with Pakistani army chief
Tweet
Share
E-mailGet Alerts ABMD Hot Sheet
Price: $381.02 --0%
Rating Summary:
7 Buy, 12 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 12 | Down: 17 | New: 31
Rating Summary:
7 Buy, 12 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 12 | Down: 17 | New: 31
Join SI Premium – FREE
Lazard Capital downgraded ABIOMED (NASDAQ: ABMD) from Buy to Neutral.
For an analyst ratings summary and ratings history on ABIOMED click here. For more ratings news on ABIOMED click here.
Shares of ABIOMED closed at $24.29 yesterday.
For an analyst ratings summary and ratings history on ABIOMED click here. For more ratings news on ABIOMED click here.
Shares of ABIOMED closed at $24.29 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Barclays cuts Cirrus Logic price target to $95 from $130, cuts to Underweight
- H.C. Wainwright Downgrades Silence Therapeutics (SLN) to Neutral
- Evercore ISI Downgrades Ally Financial (ALLY) to Underperform
Create E-mail Alert Related Categories
DowngradesRelated Entities
LazardSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
